Primary cutaneous diffuse large B‐cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences

Primary cutaneous diffuse large B‐cell lymphoma, NOS (PCLBCL/NOS) is a rare PCLBCL. Only few data are available for this tumor. The aim of this study was to identify clinical and/or immunohistochemical markers (in addition to Bcl‐2) that characterize PCLBCL/NOS, assist in differentiating it from PCLBCL, leg type (PCLBCL/LT) and help to assess the clinical course/prognosis.

[1]  L. Cerroni,et al.  Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. , 2018, The Journal of investigative dermatology.

[2]  Elizabeth J. Osterlund,et al.  BCL-2 family proteins: changing partners in the dance towards death. , 2018 .

[3]  Elizabeth J. Osterlund,et al.  BCL-2 family proteins: changing partners in the dance towards death , 2017, Cell Death and Differentiation.

[4]  M. Schön,et al.  Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma—New Therapeutic Targets , 2017, The American journal of surgical pathology.

[5]  S. Ascani,et al.  Primary cutaneous B‐cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers , 2016, Cancer medicine.

[6]  D. Cappellen,et al.  MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma. , 2016, The Journal of investigative dermatology.

[7]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[8]  J. Becker,et al.  Aggressive primary cutaneous B‐cell lymphomas show increased Angiopoietin‐2‐induced angiogenesis , 2015, Experimental dermatology.

[9]  S. Suster,et al.  Can Cutaneous Low-Grade B-cell Lymphoma Transform Into Primary Cutaneous Diffuse Large B-cell Lymphoma? An Immunohistochemical Study of 82 cases , 2014, The American Journal of dermatopathology.

[10]  W. Kempf,et al.  Cutaneous Lymphomas: An Update. Part 2 B-Cell Lymphomas and Related Conditions , 2014, The American Journal of dermatopathology.

[11]  Kai Fu,et al.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. , 2014, Blood.

[12]  C. Klemke.  Cutaneous lymphomas , 2014, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[13]  M. Felcht,et al.  Expression of the T‐cell regulatory marker FOXP3 in primary cutaneous large B‐cell lymphoma tumour cells , 2012, The British journal of dermatology.

[14]  C. Sander,et al.  B‐Zell‐Lymphome der Haut , 2012 .

[15]  S. Suster,et al.  The Histomorphologic Spectrum of Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Study of 79 Cases , 2011, The American Journal of dermatopathology.

[16]  H. Schulze,et al.  Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study. , 2011, Acta dermato-venereologica.

[17]  Kai Fu,et al.  Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Willemze,et al.  IgM Expression on Paraffin Sections Distinguishes Primary Cutaneous Large B-cell Lymphoma, Leg Type From Primary Cutaneous Follicle Center Lymphoma , 2010, The American journal of surgical pathology.

[19]  Kai Fu,et al.  A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy , 2009, Clinical Cancer Research.

[20]  Angelica Selim,et al.  TNM Classification System for Primary Cutaneous Lymphomas , 2008 .

[21]  R. Dummer,et al.  European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. , 2008, Blood.

[22]  L. French,et al.  Primary cutaneous B-cell lymphomas – Clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome , 2008, Leukemia & lymphoma.

[23]  T. Petrella,et al.  Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. , 2007, Archives of dermatology.

[24]  C. Klemke,et al.  Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG) , 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[25]  C. Meijer,et al.  Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Schulze,et al.  New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas. , 2007, Journal of the American Academy of Dermatology.

[27]  C. Meijer,et al.  Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma , 2006, Modern Pathology.

[28]  S. Pileri,et al.  Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Nicola Pimpinelli,et al.  WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects , 2005, Journal of cutaneous pathology.

[30]  C. Massone,et al.  Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. , 2005, Blood.

[31]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[32]  Remco Dijkman,et al.  Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. , 2005, Blood.

[33]  T. Petrella,et al.  Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. , 2004, Blood.

[34]  M. Felcht,et al.  The value of molecular diagnostics in primary cutaneous B-cell lymphomas in the context of clinical findings, histology, and immunohistochemistry. , 2011, Journal of the American Academy of Dermatology.

[35]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[36]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[37]  H. Kerl,et al.  [Primary cutaneous B-cell lymphomas]. , 2004, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.